GlassScriptPhysician profile
Lonna S Bufford
NPI 1790952067
$3,876.66
in general payments reported to CMS, 2019-2025
33 companies · $649 in 2025
The $649 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $327 · 2021: $502 · 2022: $716 · 2023: $677 · 2024: $698 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,954 · Education: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,953.76 |
| Education | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $834.22 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $456.17 | 2019-2025 | |
| Novo Nordisk INC | $298.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $266.55 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Amgen INC. | $248.53 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $202.69 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $187.54 | 2021-2025 | Freestyle Libre, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $160.22 | 2019-2025 | Airsupra |
| Merck Sharp & Dohme LLC | $153.77 | 2019-2025 | Dificid, Capvaxive, Gardasil 9 |
| Currax Pharmaceuticals LLC | $92.86 | 2020-2023 | Nexletol, Contrave, Onzetra Xsail |
| Allergan, INC. | $90.11 | 2019-2020 | |
| Horizon Therapeutics Plc | $82.25 | 2019-2021 | |
| Genentech USA, INC. | $74.95 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.13 | 2020-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.96 | 2021-2024 | Trulance, Xifaxan |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $56.28 | 2025 | Azstarys |
| Kowa Pharmaceuticals America, INC. | $55.22 | 2019-2024 | Zoryve |
| Sanofi Pasteur INC. | $54.29 | 2020-2023 | |
| Biohaven Pharmaceuticals, INC. | $54.03 | 2021 | |
| Dexcom, INC. | $51.13 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $41.76 | 2020-2025 | |
| Astellas Pharma US INC | $41.35 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.71 | 2022-2023 | |
| Collegium Pharmaceutical, INC. | $34.74 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $32.00 | 2021-2022 | |
| Exact Sciences Corporation | $31.75 | 2023 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $17.35 | 2023 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $16.29 | 2024 | Voquezna |
| Bausch Health US, LLC | $15.85 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.70 | 2022 | |
| Shire North American Group INC | $13.91 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.44 | 2020 | |
| Janssen Pharmaceuticals, INC | $10.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lonna Bufford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.